StockViz
Share URL
Embed chart view
-
Export .csv
-
Download image
-
Copy link
-
Embed code
StockViz
RANKINGS
Knight Therapeutics Inc.
Toronto Stock Exchange:GUD.TO
Sector
Location
Market Cap
USD 439.04 M
Share Price
USD 4.41
Avg Daily Volume
58,652
Change (1 day)
-2.37%
Change (1 year)
5.82%
Change (YTD)
18.76%
Knight Therapeutics Inc. EBITDA for the year ending December 31, 2024: USD 44.74 M
Knight Therapeutics Inc. EBITDA is USD 44.74 M for the year ending December 31, 2024, a 44.99% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
-
Knight Therapeutics Inc. EBITDA for the year ending December 31, 2023 was USD 30.86 M, a 65.58% change year over year.
-
Knight Therapeutics Inc. EBITDA for the year ending December 31, 2022 was USD 18.64 M, a -44.66% change year over year.
-
Knight Therapeutics Inc. EBITDA for the year ending December 31, 2021 was USD 33.67 M, a -36.49% change year over year.
-
Knight Therapeutics Inc. EBITDA for the year ending December 31, 2020 was USD 53.02 M, a 153.72% change year over year.
Competitors
Eli Lilly and Company
USD 771.71
LLY
+10.21
1.34%
AbbVie Inc.
USD 189.26
ABBV
-2.14
-1.12%
Roche Holding AG
USD 340.88
RO.SW
+2.44
0.72%
AstraZeneca PLC
USD 138.02
AZN.L
-0.31
-0.22%
Merck & Co., Inc.
USD 79.96
MRK
-1.56
-1.91%
Amgen Inc.
USD 294.76
AMGN
-3.49
-1.17%
Pfizer Inc.
USD 24.47
PFE
-0.11
-0.45%
Gilead Sciences, Inc.
USD 108.22
GILD
-0.58
-0.53%
Sanofi
USD 96.63
SAN.PA
-0.24
-0.24%
Bristol-Myers Squibb Company
USD 47.36
BMY
-0.70
-1.46%
Chugai Pharmaceutical Co., Ltd.
USD 47.05
4519.T
+0.49
1.05%
GSK plc
USD 18.07
GSK.L
-0.88
-4.65%
Regeneron Pharmaceuticals, Inc.
USD 542.52
REGN
-7.48
-1.36%
Cencora, Inc.
USD 292.87
COR
-1.51
-0.51%
Jiangsu Hengrui Medicine Co., Ltd.
USD 8.18
600276.SS
+0.14
1.80%
Takeda Pharmaceutical Company Limited
USD 29.16
4502.T
-0.53
-1.77%
Haleon plc
USD 4.81
HLN.L
-0.00
-0.08%
Daiichi Sankyo Company, Limited
USD 24.17
4568.T
+0.03
0.11%
Ucb S.A.
USD 203.26
UCB.BR
+1.51
0.75%
BeOne Medicines Ltd.
USD 294.55
ONC
+4.20
1.45%
Key Data
| Date | EBITDA | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) |
|---|
Competitors
Eli Lilly and Company
USD 771.71
LLY
+10.21
1.34%
AbbVie Inc.
USD 189.26
ABBV
-2.14
-1.12%
Roche Holding AG
USD 340.88
RO.SW
+2.44
0.72%
AstraZeneca PLC
USD 138.02
AZN.L
-0.31
-0.22%
Merck & Co., Inc.
USD 79.96
MRK
-1.56
-1.91%
Amgen Inc.
USD 294.76
AMGN
-3.49
-1.17%
Pfizer Inc.
USD 24.47
PFE
-0.11
-0.45%
Gilead Sciences, Inc.
USD 108.22
GILD
-0.58
-0.53%
Sanofi
USD 96.63
SAN.PA
-0.24
-0.24%
Bristol-Myers Squibb Company
USD 47.36
BMY
-0.70
-1.46%
Chugai Pharmaceutical Co., Ltd.
USD 47.05
4519.T
+0.49
1.05%
GSK plc
USD 18.07
GSK.L
-0.88
-4.65%
Regeneron Pharmaceuticals, Inc.
USD 542.52
REGN
-7.48
-1.36%
Cencora, Inc.
USD 292.87
COR
-1.51
-0.51%
Jiangsu Hengrui Medicine Co., Ltd.
USD 8.18
600276.SS
+0.14
1.80%
Takeda Pharmaceutical Company Limited
USD 29.16
4502.T
-0.53
-1.77%
Haleon plc
USD 4.81
HLN.L
-0.00
-0.08%
Daiichi Sankyo Company, Limited
USD 24.17
4568.T
+0.03
0.11%
Ucb S.A.
USD 203.26
UCB.BR
+1.51
0.75%
BeOne Medicines Ltd.
USD 294.55
ONC
+4.20
1.45%